This information is current as Enhances the Cytotoxicity of Fas Ligand Inhibition of Metalloproteinase Cleavage

The Fas ligand (FasL)/Fas receptor (CD95) pathway is an important mediator of apoptosis in the immune system and can also mediate cancer cell death. Soluble FasL (sFasL), shed from the membrane-bound form of the molecule by a putative metalloproteinase (MP), may function to locally regulate the activity of membrane-bound FasL. Using a replication-defective recombinant adenovirus-expressing FasL (RAdFasL), we identified a variable ability of different carcinoma cells to respond to FasL-induced cytotoxicity and to shed sFasL. Blockade of FasL cleavage with an MP inhibitor significantly enhanced RAdFasL-induced apoptosis suggesting that sFasL may antagonize the effect of membrane-bound FasL. In support of this concept, a recombinant adenovirus expressing a noncleavable form of FasL (RAdD4) was found to be a potent inducer of apoptosis even at very low virus doses. Our results highlight the therapeutic potential of noncleavable FasL as an antitumor agent and emphasize the important role of MP via the production of sFasL in regulating the response of the Fas pathway. Moreover, these findings have general implications for the therapeutic exploitation of TNF family ligands and for the possible impact of MP-based therapies on the normal physiology of Fas/TNF pathways. The Journal of Immunology, 2003, 170: 677–685.

[1]  C. Ware.  April and Baff Connect Autoimmunity and Cancer , 2000, The Journal of experimental medicine.

[2]  R. Caspi,et al.  Fas and Fas Ligand Expressed on Cells of the Immune System, not on the Target Tissue, Control Induction of Experimental Autoimmune Uveitis , 2000, The Journal of Immunology.

[3]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[4]  A. Barber,et al.  Matrix metalloproteinase inhibition protects hepatic integrity in hemorrhagic shock , 2000, Journal of Gastrointestinal Surgery.

[5]  D. Adams,et al.  CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily , 2000, Molecular and Cellular Biology.

[6]  J. Desbarats,et al.  Fas engagement accelerates liver regeneration after partial hepatectomy , 2000, Nature Medicine.

[7]  T. Shaw,et al.  Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis , 2000, Expert opinion on investigational drugs.

[8]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[9]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[11]  A. Strasser,et al.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Kripke,et al.  Fas ligand: a sensor for DNA damage critical in skin cancer etiology. , 1999, Science.

[13]  A. Fontana,et al.  Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. , 1999, Journal of immunology.

[14]  R. Crystal,et al.  Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. , 1999, Human gene therapy.

[15]  D. Tang,et al.  Cycloheximide-induced T-cell Death Is Mediated by a Fas-associated Death Domain-dependent Mechanism* , 1999, The Journal of Biological Chemistry.

[16]  G. Miller,et al.  Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells , 1999, Cell Death and Differentiation.

[17]  D. Taub,et al.  Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. , 1999, Blood.

[18]  F. Shanahan,et al.  The Fas counterattack: cancer as a site of immune privilege. , 1999, Immunology today.

[19]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[20]  S. Nagata,et al.  Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.

[21]  S. Yamamoto,et al.  Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. , 1998, Human gene therapy.

[22]  D. Kerr,et al.  Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells , 1998, Gene Therapy.

[23]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[24]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[25]  P. Möller,et al.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. , 1998, Cancer research.

[26]  T. Ochi,et al.  Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing , 1997, The Journal of experimental medicine.

[27]  E. Nabel,et al.  Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Matsuzawa,et al.  Requirement of Fas for the Development of Autoimmune Diabetes in Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.

[29]  P. McCann,et al.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.

[30]  S. Nagata,et al.  Essential roles of the Fas ligand in the development of hepatitis , 1997, Nature Medicine.

[31]  C. Janeway,et al.  The Role of Fas in Autoimmune Diabetes , 1997, Cell.

[32]  O. Yoshida,et al.  Doxorubicin sensitizes human bladder carcinoma cells to Fas‐mediated cytotoxicity , 1997, Cancer.

[33]  S. Nagata,et al.  Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. , 1997, Journal of immunology.

[34]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[35]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[36]  M. Todaro,et al.  Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis , 1997, Science.

[37]  C. Stoeckert,et al.  Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice , 1996, Science.

[38]  L. French,et al.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover , 1996, The Journal of cell biology.

[39]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[40]  K. Yoshino,et al.  Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .

[41]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[42]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[43]  Masato Tanaka,et al.  Expression of the functional soluble form of human fas ligand in activated lymphocytes. , 1995, The EMBO journal.

[44]  T. Saito,et al.  Fas-mediated cytotoxicity by freshly isolated natural killer cells , 1995, The Journal of experimental medicine.

[45]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[46]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[47]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[48]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[49]  N. Copeland,et al.  The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. , 1992, Journal of immunology.

[50]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[51]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[52]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.